ArticleScientific reports2019
Human mesenchymal stem cell sheets in xeno-free media for possible allogenic applications.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Self-assembling multilayer MSC-sheet promotes wound healing increasing M2 macrophage polarization.Scientific reports · 2025Article
- Optimal good manufacturing practice-compliant production of dental follicle stem cell sheet and its application in Sprague-Dawley rat periodontitis.World journal of stem cells · 2025Article
- Human platelet lysate-cultured adipose-derived stem cell sheets promote angiogenesis and accelerate wound healing via CCL5 modulation.Stem cell research & therapy · 2024Article
- Schisandrin B Improves the Hypothermic Preservation of Celsior Solution in Human Umbilical Cord Mesenchymal Stem Cells.Tissue engineering and regenerative medicine · 2023Article
- Article
- Application of mesenchymal stem cell sheet for regeneration of craniomaxillofacial bone defects.Stem cell research & therapy · 2023Review
- Engineering approaches to investigate the roles of lymphatics vessels in rheumatoid arthritis.Microcirculation (New York, N.Y. : 1994) · 2023Review
- Rapid and effective preparation of clonal bone marrow-derived mesenchymal stem/stromal cell sheets to reduce renal fibrosis.Scientific reports · 2023Article
- Preparation and characterization of morphine gelatine microspheres.Designed monomers and polymers · 2023Article
- Mesenchymal Stem Cell Sheet Centrifuge-Assisted Layering Augments Pro-Regenerative Cytokine Production.Cells · 2022Article
- Article
- Enhancement of Lymphangiogenesis by Human Mesenchymal Stem Cell Sheet.Advanced healthcare materials · 2022Article
- Preclinical study of human umbilical cord mesenchymal stem cell sheets for the recovery of ischemic heart tissue.Stem cell research & therapy · 2022Article
- Application of mesenchymal stem cell sheet to treatment of ischemic heart disease.Stem cell research & therapy · 2021Review
- 3D cell sheet structure augments mesenchymal stem cell cytokine production.Scientific reports · 2021Article
- Review
- Design of Temperature-Responsive Cell Culture Surfaces for Cell Sheet Engineering.Cyborg and bionic systems (Washington, D.C.) · 2021Review
- Novel therapies using cell sheets engineered from allogeneic mesenchymal stem/stromal cells.Emerging topics in life sciences · 2020Review
- Modeling Rheumatoid Arthritis In Vitro: From Experimental Feasibility to Physiological Proximity.International journal of molecular sciences · 2020Review
- Antibody drug separation using thermoresponsive anionic polymer brush modified beads with optimised electrostatic and hydrophobic interactions.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-based therapies are increasingly focused on allogeneic stem cell sources because of several advantages in eliminating donor variability (e.g., aging and disease pathophysiology) affecting stem cell quality and in cell-banked sourcing of healthy donors to enable "off-the-shelf" products. However, allogeneic cell therapy is limited by host patient immunologic competence and inconsistent performance due to cell delivery methods. To address allogeneic cell therapy limitations, this study developed a new allogeneic stem cell sheet using human umbilical cord mesenchymal stem cells (hUC-MSC) that present low antigenicity (i.e., major histocompatibility complex, MHC). Optimal conditions including cell density, passage number, and culture time were examined to fabricate reliable hUC-MSC sheets. MHC II antigens correlated to alloimmune rejection were barely expressed in hUC-MSC sheets compared to other comparator MSC sheets (hBMSC and hADSC). hUC-MSC sheets easily graft spontaneously onto subcutaneous tissue in immune-deficient mice within 10 minutes of placement. No sutures are required to secure sheets to tissue because sheet extracellular matrix (ECM) actively facilitates cell-target tissue adhesion. At 10 days post-transplantation, hUC-MSC sheets remain on ectopic target tissue sites and exhibit new blood vessel formation. Furthermore, implanted hUC-MSC sheets secrete human HGF continuously to the murine target tissue. hUC-MSC sheets described here should provide new insights for improving allogenic cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.